Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasms × selpercatinib × Clear all

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Thyroid Neoplasms 4 Thyroid Cancer, Papillary 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Carcinoma, Anaplastic 1 Sexual Dysfunction, Physiological 1 Neoplasms 1 Gastrointestinal Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Carcinoma, Medullary 1 Cachexia-Anorexia Syndrome 1 Breast Neoplasms 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1 Adenocarcinoma, Follicular 1

Interventions

Surveys and Questionnaires 114 Exercise 102 Blood Specimen Collection 98 Radiotherapy 66 Gemcitabine 64 Bevacizumab 57 Cisplatin 55 Standard of Care 54 Cyclophosphamide 51 Capecitabine 50 Carboplatin 49 Docetaxel 47 Dexamethasone 46 pembrolizumab 45 Paclitaxel 45 Interviews as Topic 43 Oxaliplatin 40 Magnetic Resonance Spectroscopy 38 Fluorouracil 37 Methods 36 Irinotecan 36 Therapeutics 33 Drug Therapy 32 Radiosurgery 31 Nivolumab 30 Erlotinib Hydrochloride 27 Educational Status 26 Everolimus 24 Leucovorin 23 Control Groups 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡